
Parvinder Kaur

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1990316/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pharmacokinetics-Pharmacodynamics of Rifampin in an Aerosol Infection Model of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2003, 47, 2118-2124.	3.2	322
2	Moxifloxacin, Ofloxacin, Sparfloxacin, and Ciprofloxacin against <i>Mycobacterium tuberculosis</i> : Evaluation of In Vitro and Pharmacodynamic Indices That Best Predict In Vivo Efficacy. Antimicrobial Agents and Chemotherapy, 2007, 51, 576-582.	3.2	203
3	Isoniazid Pharmacokinetics-Pharmacodynamics in an Aerosol Infection Model of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2004, 48, 2951-2957.	3.2	151
4	Azaindoles: Noncovalent DprE1 Inhibitors from Scaffold Morphing Efforts, Kill Mycobacterium tuberculosis and Are Efficacious <i>in Vivo</i> . Journal of Medicinal Chemistry, 2013, 56, 9701-9708.	6.4	140
5	Delineating Bacteriostatic and Bactericidal Targets in Mycobacteria Using IPTG Inducible Antisense Expression. PLoS ONE, 2009, 4, e5923.	2.5	56
6	Polyphosphate Kinase from M. tuberculosis: An Interconnect between the Genetic and Biochemical Role. PLoS ONE, 2010, 5, e14336.	2.5	18
7	Mannose-conjugated chitosan nanoparticles for delivery of Rifampicin to Osteoarticular tuberculosis. Drug Delivery and Translational Research, 2021, 11, 1509-1519.	5.8	17
8	A High-Throughput Cidality Screen for Mycobacterium Tuberculosis. PLoS ONE, 2015, 10, e0117577.	2.5	15
9	A multi-targeting pre-clinical candidate against drug-resistant tuberculosis. Tuberculosis, 2021, 129, 102104.	1.9	12
10	Novel lead generation of an anti-tuberculosis agent active against non-replicating mycobacteria: exploring hybridization of pyrazinamide with multiple fragments. Medicinal Chemistry Research, 2015, 24, 2986-2992.	2.4	11
11	Unravelling the Secrets of Mycobacterial Cidality through the Lens of Antisense. PLoS ONE, 2016, 11,	2.5	6